SecBot SecBot

VNDA

Vanda Pharmaceuticals Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001347178 Biotech & Drug Discovery
$3.81 −0.18 (−4.51%)
Nov 16 4:00 PM ET · prev $3.99
Market cap
$238.9M
Micro cap
Consensus
Buy
82% Buy or better · 11 analysts
Median target
🔒 Subscribers only
1 year
−13.4%
from $4.40 · Nov 17
30 days
−6.8%
from $4.09
52-week range
$3.59–9.56
−60% from high · low Nov 5
Avg volume 20D
1.31M
shares / day
Short interest
7.62M
≈12.6% of shares · −8.3%
Days to cover
5.9
at average volume
Insider net
−$1.8M
1 buyer · 3 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Reddit crowd
58°
Warm · 2 mentions this week
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/6 ·Next FDA decision date, Dec 12, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $38.1K at an average $3.81. 3 insiders sold $1.9M.

  • InstitutionsMIXED

    Q3 2026: 17 added (0 new), 20 trimmed or exited.

  • AnalystsBULLISH

    9 of 11 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.362 → −$0.302 over 90 days.

  • Short sellersSTEADY

    Short interest −8.3% to 7.62M shares. 5.9 days to cover, ≈12.6% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

  • SocialQUIET

    Crowd 58° (warm) this week from 2 mentions: 1 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPADD2,082,839$10.2M
FEDERATED HERMES, INC.DOUBLED1,599,636$7.9M
Qube Research & Technologies LtdADD1,251,629$6.1M
FMR LLCDOUBLED302,936$1.5M
BARCLAYS PLCDOUBLED189,672$931.3K
KLP KAPITALFORVALTNING ASADD184,800$907.4K
IEQ CAPITAL, LLCTRIM130,281$639.7K
Connor, Clark & Lunn Investment Management Ltd.TRIM126,267$620.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 82% rate it Buy or better
Strong Buy3Buy6Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 5, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 23, 2026Oppenheimer
INITIATE
INITIATEOutperform
Aug 10, 2026B. Riley Securities
REITERATE
REITERATEBuy
Aug 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
AQR Capital Management filed an amended Schedule 13G disclosing a 3.47% passive stake in Vanda Pharmaceuticals as of…
SC 13G/A · Impact 2/10
Nov 10, 2026 SEC
State Street Corporation filed a Schedule 13G disclosing a 5.0% passive stake in Vanda Pharmaceuticals as of September…
SC 13G · Impact 3/10
Nov 5, 2026 Insider
Duncan Charles Cliff bought 5,803 shares
Director @ $3.80 ($22.1K)
Nov 4, 2026 Insider
Duncan Charles Cliff bought 3,447 shares
Director @ $3.82 ($13.2K)
Nov 3, 2026 Other
Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today ann
Nov 3, 2026 Insider
Duncan Charles Cliff bought 750 shares
Director @ $3.80 ($2.8K)
Oct 28, 2026 SEC
Vanda Pharmaceuticals reported Q3 2026 total revenue of $69.8M, up 24% YoY and above the $69.1M consensus, driven by…
8-K · Impact 6/10
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · ADD
2,082,839 shares ($10.2M)

Insider ledger

Form 4
$38.1K
bought · 1 insider
$1.9M
sold · 3 insiders
+0.0%
vs their $3.81 cost
DateInsiderTypeValue
Nov 5, 2026
Duncan Charles Cliff
Director
Nov 5, 2026
BUY$22.1K
Nov 4, 2026
Duncan Charles Cliff
Director
Nov 4, 2026
BUY$13.2K
Nov 3, 2026
Duncan Charles Cliff
Director
Nov 3, 2026
BUY$2.8K
Jun 4, 2026
Mitchell Stephen Ray
Director
Jun 4, 2026
AWARD41,600 sh
Jun 4, 2026
Honore Tage
Director
Jun 4, 2026
AWARD41,600 sh
Jun 4, 2026
Ward Anne Sempowski
Director
Jun 4, 2026
AWARD41,600 sh
Jun 4, 2026
Duncan Charles Cliff
Director
Jun 4, 2026
AWARD41,600 sh
Jun 4, 2026
Chrousos Phaedra
Director
Jun 4, 2026
AWARD41,600 sh

Earnings setup

Estimates
−$0.30
EPS estimate, this quarter
+17%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.30-$0.39–-$0.23+38.9%$70.1M
Next Q-$0.25-$0.32–-$0.16+39.8%$72.4M
Current FY-$2.52-$2.61–-$2.45+16.7%$242.1M
Next FY-$0.74-$1.47–$0.07+23.0%$316.3M

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
7,623,705
shares short
-8.3%
vs prior settlement
5.9
days to cover
≈12.6%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Upcoming
Recent
Nov 3, 2026
Press release
Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the…
Oct 28, 2026
Earnings result
VNDA Q3 2026 Earnings: EPS $-0.37 (+46.8% vs est)
Oct 21, 2026
Earnings
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it…
Oct 19, 2026
Clinical Trial
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
Phase 3 · COMPLETED
Oct 14, 2026
Press release
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765…
Reddit
Crowd this week 58° Warm 1 bullish · 0 bearish
Mentions, 7 days 2 1 in posts · 1 in comments
Recent posts
Recent comments
All social signals and their track records

SecBot reports

8 filings · 1 bullish · 0 bearish · 1 mixed · 6 neutral
All VNDA filing & press-release reports (8)